The Role of Cerebrospinal Fluid in Personalized Alzheimer Disease Care: Betty Tijms, PhD

WATCH TIME: 3 minutes | Captions are auto-generated and may contain errors.

“Not every patient is the same, and patients probably need their own treatments.”

As Alzheimer disease (AD) research continues to move toward more personalized approaches to diagnosis and treatment, researchers are increasingly focused on understanding the biological differences that may exist from one patient to the next. Advances in biomarker technology are making it possible to characterize disease biology in greater detail, with emerging tools offering new opportunities to identify distinct biological variants of AD and better understand the processes underlying symptoms.

The 2026 Alzheimer’s Association International Conference (AAIC), held July 12-15 in London, brought together researchers and clinicians from around the world to discuss the latest advances in Alzheimer disease research, diagnosis, and treatment. During the meeting, NeurologyLive^® spoke with Betty Tijms, PhD, head of science at the Alzheimer’s Cetner in Amsterdam, about emerging approaches to better characterize the biological complexity of AD.

With growing recognition that AD can vary substantially from one patient to the next, researchers are exploring more personalized approaches to diagnosis and treatment. Throughout the interview, Tijms discussed the importance of understanding the biological processes underlying an individual's symptoms, including the potential of emerging biomarker technologies to identify distinct biological variants of the disease. She also addressed advances in blood-based biomarkers and the continued importance of comprehensive measures of brain biology in developing more targeted, personalized therapies.

Click here for more AAIC 2026 coverage.